Joint modeling of longitudinal ordinal data and competing risks survival times and analysis of the NINDS rt-PA stroke trial

Stat Med. 2010 Feb 28;29(5):546-57. doi: 10.1002/sim.3798.


Existing joint models for longitudinal and survival data are not applicable for longitudinal ordinal outcomes with possible non-ignorable missing values caused by multiple reasons. We propose a joint model for longitudinal ordinal measurements and competing risks failure time data, in which a partial proportional odds model for the longitudinal ordinal outcome is linked to the event times by latent random variables. At the survival endpoint, our model adopts the competing risks framework to model multiple failure types at the same time. The partial proportional odds model, as an extension of the popular proportional odds model for ordinal outcomes, is more flexible and at the same time provides a tool to test the proportional odds assumption. We use a likelihood approach and derive an EM algorithm to obtain the maximum likelihood estimates of the parameters. We further show that all the parameters at the survival endpoint are identifiable from the data. Our joint model enables one to make inference for both the longitudinal ordinal outcome and the failure times simultaneously. In addition, the inference at the longitudinal endpoint is adjusted for possible non-ignorable missing data caused by the failure times. We apply the method to the NINDS rt-PA stroke trial. Our study considers the modified Rankin Scale only. Other ordinal outcomes in the trial, such as the Barthel and Glasgow scales, can be treated in the same way.

MeSH terms

  • Algorithms
  • Computer Simulation / statistics & numerical data
  • Humans
  • Likelihood Functions
  • Longitudinal Studies
  • Models, Statistical
  • Odds Ratio
  • Proportional Hazards Models
  • Randomized Controlled Trials as Topic / statistics & numerical data*
  • Recombinant Proteins / therapeutic use*
  • Risk
  • Stroke / drug therapy*
  • Stroke / mortality*
  • Survival Analysis
  • Tissue Plasminogen Activator / therapeutic use*
  • United States


  • Recombinant Proteins
  • Tissue Plasminogen Activator